Immunization Newsbriefs
Link to Main Page
  Back Search the Site Send Your Feedbck  
Immunization Newsbriefs
Read Current Issue Online
Search Newsbriefs Archives
Subscribe to Email Online
Unsubscribe from Email Online
About NNii
Vaccine Information
Health Professionals
Policy Makers
Read Current Newsbriefs

Chiron Exploring the Growth Potential in Flu Vaccines
Los Angeles Times; C6
Gellene, Denise


After its purchase of PowderJect Pharmaceuticals of England, the biotechnology firm Chiron became the second-largest maker of influenza vaccine in the United States. The Emeryville, Calif., company sold all of its flu vaccine stock during the 2003-2004 influenza season, boosting its revenue by $245 million--but Chiron is looking toward a much larger global market, believing that the world's flu vaccine needs could reach $2.6 billion over the coming 10 years, due in part to a U.S. target of 150 million annual flu vaccinations. Chiron is now putting $100 million into its vaccine research and development program to create a quicker method of producing flu vaccine than the current standard of growing the vaccine inside chicken eggs, which takes a significant amount of time and cannot be sped up.

© Copyright National Network for Immunization Information. The information contained in the National Network for Immunization Information Web site should not be used as a substitute for the medical care and advice of your health care provider. There may be variations in treatment that your health care provider may recommend based on individual facts and circumstances.